← SynDRA
NETUPITANT
SynDRA canonical compound SYN0006135 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | TACR1 |
|---|
| Mechanism of action | Tachykinin antagonist |
|---|
| Indication | nausea | vomiting |
|---|
| Disease area | gastroenterology |
|---|
All known targets
Mechanisms of action (all sources)
- Tachykinin antagonist
- TACR1 ANTAGONIST
- Neurokinin 1 receptor antagonist
- neurokinin receptor antagonist
Drug classes
- Neurokinin 1 Antagonists
- Substance P/Neurokinin-1 Receptor Antagonist
- Cytochrome P450 3A4 Inhibitors
- P-Glycoprotein Inhibitors
- Breast Cancer Resistance Protein Inhibitors
Cross-references
Synonyms
- Ro 67-3189/000
- RO-67-3189/000
- RO-67-3189
- RO-673189000
- Netupitant component of akynzeo
- Netupitant component of akynzeo capsule
- R-1124
- NK1 antagonist (emesis), Roche
- Ro-67-3189
- RO 673189000
- CHEBI:85155
- AKYNZEO CAPSULE COMPONENT NETUPITANT
- NETUPITANT COMPONENT AKYNZEO CAPSULE
- D05152
- netupitantum
- RefChem:832394
- DTXCID60105762
- RO-67-3189 000
- MFCD25976831
- C30H32F6N4O
- Netupitant [USAN]
- Netupitant [USAN:INN]
- UNII-7732P08TIR
- Netupitant (Standard)
- NETUPITANT [MI]
- NETUPITANT [INN]
- Netupitant (USAN/INN)
- NETUPITANT [VANDF]
- NETUPITANT [WHO-DD]
- SCHEMBL445804
- GTPL5742
- orb1300358
- Netupitant(CID-6451149)
- NETUPITANT [ORANGE BOOK]
- SCHEMBL29809811
- GLXC-15009
- HMS3887E19
- HMS5087B14
Reported adverse events
- Constipation
- Dyspepsia
- Erythema
- Fatigue
- Headache
- Hypersensitivity
- Asthenia
Look up NETUPITANT in the interactive SynDRA portal →